Newbury Pharmaceuticals (NEWBRY) Q1 2026 earnings summary

Executive summary

• Net revenue for Q1 (Sep–Nov 2025) was SEK 11.7 million, up from SEK 6.5 million year-over-year, driven entirely by Nordic sales.

• EBITDA was SEK -5.5 million, with operating cash flow at SEK -6.5 million, reflecting expansion costs and non-recurring severance expenses.

• The company secured generic approvals for Ivermectin and Mirtazapin and appointed its founder as CEO.

• Portfolio includes about 20 launched products in the Nordics, expected to exceed 30 by end of 2026.

Financial highlights

• Net revenue increased 79% year-over-year to SEK 11.7 million.

• EBITDA was SEK -5.5 million (vs. SEK -3.8 million last year); EBIT was SEK -6.1 million (vs. SEK -4.2 million).

• Result before tax was SEK -6.5 million (vs. SEK -4.6 million last year).

• Cash at period end was SEK 7.9 million, down from SEK 19.4 million year-over-year.

• Operating cash flow was SEK -6.5 million (vs. SEK 4.8 million last year).

Outlook and guidance

• Continued growth phase with focus on expanding the product portfolio and strengthening tender competitiveness.

• International sales expected to resume and grow as regulatory progress continues.

• Ongoing focus on cost management and reducing earnings volatility.